C

Cala Health

FDA-approved wearable tremor therapy device

Accounting Manager

Full-TimeUpdated on 10/23/2026
$130k - $150k
Senior
Bachelor's
San Mateo, CA, USA
HybridHybrid; requires 3 days per week at the San Mateo office.
AccountingFinancial Accounting
H1B Sponsorship Available

About the job

Requirements
  • At least 6 years of experience working in a public company or as an auditor.
  • A CPA designation or equivalent certification is required.
  • A bachelor's degree in Finance, Accounting, or equivalent is required.
  • Strong understanding of U.S. generally accepted accounting principles is required.
  • Ability to work independently with minimal supervision and strong analytical skills and attention to detail.
  • Ability to apply policies and standards consistently and meet deadlines.
Responsibilities
  • Lead month-, quarter-, and year-end close processes, managing journal entries, reconciliations, and complex revenue, cost of goods sold, and research and development/clinical accruals.
  • Perform monthly budget variance and quarterly flux analyses, preparing routine and ad hoc accounting schedules for internal and external stakeholders.
  • Serve as the U.S. generally accepted accounting principles subject matter expert, author technical memos, and build process flowcharts.
  • Act as the primary contact for external and internal auditors, maintain Sarbanes-Oxley compliance procedures, and manage state sales tax submissions.
  • Oversee financial systems, assist with enterprise resource planning implementations, design internal controls, and partner cross-functionally to improve accounting processes.
Desired Qualifications
  • Big Four experience is a plus.
  • Experience dealing with initial public offering or public company clients is strongly recommended.
  • People management experience is a plus.
  • Experience with enterprise resource planning systems is a plus.

About the company

Cala Health develops the Cala kIQ System, a physician-prescribed wearable that treats hand tremors from essential tremor and Parkinson’s disease using TAPS therapy. TAPS is a non-invasive electrical stimulation of skin nerves delivered via the wearable during roughly 40-minute sessions to reduce tremors. The device collects patient data to help patients and doctors monitor progress and tailor care, blending non-drug therapy with existing medications. It differentiates itself by FDA-approved, physician-prescribed, non-invasive, data-driven therapy that complements medical treatment, with the goal of improving daily tremor management and supporting measurable clinical outcomes.

Company Size

51-200

Company Stage

Growth Equity (Venture Capital)

Total Funding

$298.3M

Headquarters

San Mateo, California

Founded

2014

Get referred to Cala Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Trinity Capital committed $50 million on April 20, 2026, funding commercial expansion.
  • FDA cleared Cala kIQ Plus on April 15, 2026, expanding therapy modes and calibration.
  • Cala won TIME's 2026 World's Top HealthTech Companies list on September 17, 2026.

What critics are saying

  • Medicare still limits coverage to Local Coverage Criteria, blocking broad reimbursement and slowing adoption.
  • Cala continues seeking Medicare Advantage and commercial payor coverage, exposing sales to reimbursement delays.
  • If rivals win broader reimbursement or superior outcomes, Cala's DME model loses its only moat.

What makes Cala Health unique

  • Cala kIQ Plus is the only FDA-cleared wearable for action hand tremor, September 2026.
  • TAPS therapy personalizes wrist stimulation and delivers at-home treatment without surgery or implants.
  • Medicare coverage and VA availability differentiate Cala's access channel from experimental neurology wearables.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Hybrid Work Options

Growth & Insights and Company News

6 month growth

3%

1 year growth

0%

2 year growth

2%
Longevity.Technology
Oct 7th, 2026
Cala launches nationwide kIQ Plus wearable for hand tremor.

Cala launches nationwide kIQ Plus wearable for hand tremor. San Mateo-based Cala has launched nationwide availability of the Cala kIQ Plus System, its next generation wearable neuromodulation device for action hand tremor in essential tremor and Parkinson's disease. The company claims the device was cleared by the FDA earlier this year and is the first and only wearable to offer multiple stimulation waveform modes along with adaptive calibration to personalize therapy. A study of the three waveform modes presented at the American Academy of Neurology annual meeting earlier this year found that patients using their preferred waveform achieved significantly greater improvement on the Bain and Findley Activities of Daily Living scale, and that 76% to 89% of participants had at least a 1 point reduction on the clinician rated TETRAS performance score. The device is available nationwide with a prescription, and the company says it is available at no cost to eligible Veterans Affairs beneficiaries and has Medicare coverage for those who meet local coverage criteria. Cala is showcasing the Cala kIQ Plus at the AAN Fall Conference in Las Vegas October 9 to 11 and continues to pursue broader coverage in Medicare Advantage and commercial plans.

Longevity.Technology
Sep 21st, 2026
Cala Health recognized among TIME's top healthtech companies of 2026.

Cala Health recognized among TIME's top healthtech companies of 2026. Cala Health has been named to TIME and Statista's World's Top HealthTech Companies 2026 list in the Medical Devices and Wearables category. The designation follows TIME and Statista research that recognizes 500 healthtech companies across six market segments and evaluates financial performance, reputation and online engagement. According to the company, its Cala TAPS therapy, delivered from a wrist-worn wearable, is the most researched wearable treatment for essential tremor. The U.S. Food and Drug Administration cleared the Cala kIQ Plus system earlier this year for action hand tremor in essential tremor and Parkinson's disease, and the company claims kIQ Plus introduces new therapy modes and adaptive calibration to personalize treatment. The Cala system is available through the Veterans Affairs health system at no cost to eligible beneficiaries and has Medicare coverage for those who meet local coverage criteria, and the company continues to seek expanded reimbursement.

Vertex Growth
May 14th, 2026
Cala Health wins 2026 MedTech Breakthrough award for Best New Neurology Technology Solution.

Cala Health wins 2026 MedTech Breakthrough award for Best New Neurology Technology Solution. Cala Health | 14 May 2026 SAN MATEO, Calif., May 8, 2026 /PRNewswire/ - Cala(R), the bioelectronic medicine leader, announced today the Cala kIQ(R) System has been named "Best New Neurology Technology Solution" as part of the 2026 MedTech Breakthrough Awards. The awards honor excellence and recognize innovation, hard work, and success in various health and medical technology categories. This year's program attracted more than 5,000 nominations from around the globe. Cala Health won the award in recognition of its groundbreaking neurology technology platform, which is transforming how patients struggling with essential tremor (ET) access and receive care. The company is part of an elite group of 2026 winners that includes Noom, Boston Scientific, Teladoc, Medtronic, DocGo, Zimmer Biomet, CVS Health, Lyra Health, Elsevier, Medidata, IQVIA, Thermo Fisher Scientific, PointClickCare, Canon Medical Systems, and Alcon/Novartis among others. "Being named the Best New Neurology Technology Solution by the MedTech Breakthrough Awards is a meaningful validation of the work our entire team has poured into making Cala TAPS(R) Therapy a reality for patients living with essential tremor," said Deanna Harshbarger, CEO of Cala Health. "For too long, people with ET have had limited options that fit into their daily lives. We set out to change that with a non-invasive, wearable therapy they can use at home. This recognition reflects not just our technology, but our commitment to expanding access. We're proud of how far we've come, and even more energized about what's ahead." The Cala kIQ system delivers TAPS Therapy through a noninvasive wrist-worn wearable neuromodulation device, which is physician-prescribed and aids in the temporary relief of hand tremors in adults with ET. The disease affects over 7 million Americans, causing uncontrollable hand and arm shaking that disrupts daily activities, and pre-existing treatment options are often insufficient or require invasive surgical options. The Cala kIQ System bridges this treatment gap and eases symptoms in the treated hand following stimulation. For more on how Cala Health is transforming neurology care, visit www.calahealth.com. About Cala*(R) Cala Health(R)* is a bioelectronic medicine company transforming the standard of care for chronic disease. The company's wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation, and its direct-to-home digital durable medical equipment (DME) platform is reshaping the delivery of prescription therapies. The Cala kIQ(R) System is the only FDA-cleared wearable device that delivers effective therapy for action hand tremor in people with essential tremor and Parkinson's disease. The Cala kIQ device is indicated to aid in the temporary relief of hand tremors in the treated hand following stimulation in adults with essential tremor. The Cala kIQ device is indicated to aid in the temporary relief of postural and kinetic hand tremor symptoms that impact some activities of daily living in the treated hand following stimulation in adults with Parkinson's disease. The Cala kIQ device delivers TAPS(TM) therapy, which provides transcutaneous afferent patterned stimulation. Caution: Federal law restricts this device to sale by or on the order of a physician. Prior to use, refer to the product labeling for complete product instructions for use, contraindications, warnings, and precautions at https://calahealth.com. SOURCE Cala Health

International Essential Tremor Foundation
May 11th, 2026
Cala health wins 2026 MedTech Breakthrough award for best New Neurology Technology Solution.

Cala health wins 2026 MedTech Breakthrough award for best New Neurology Technology Solution. SAN MATEO, Calif., May 8, 2026 /PRNewswire/ - Cala(R), the bioelectronic medicine leader, announced today the Cala kIQ(R) System has been named "Best New Neurology Technology Solution" as part of the 2026 MedTech Breakthrough Awards. The awards honor excellence and recognize innovation, hard work, and success in various health and medical technology categories.

PR Newswire
Apr 20th, 2026
Trinity Capital commits $50M to Cala Health to expand wearable tremor therapy

Trinity Capital has committed $50 million in growth capital to Cala Health, a bioelectronic medicine company developing wearable therapies for tremors. The funding will support commercial expansion of Cala's FDA-cleared kIQ System. The wearable device helps patients manage hand tremors caused by essential tremor and Parkinson's disease. Worn on the wrist, it measures individual tremor patterns and delivers personalised nerve stimulation through noninvasive electrical stimulation. The therapy is prescribed by physicians for at-home use, enabling patients to perform everyday activities like reading, writing and eating. Trinity Capital, a Phoenix-based alternative asset manager, has deployed over $5.5 billion across more than 463 investments since 2008. The partnership aims to optimise Cala's capital structure whilst accelerating product innovation and commercial growth.